Core Insights - Ascletis Pharma Inc. has received acceptance for its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class oral fatty acid synthase inhibitor aimed at treating moderate-to-severe acne vulgaris, by the China National Medical Products Administration (NMPA) [2][3] - The Phase III clinical trial results demonstrated that denifanstat (ASC40) met all primary and secondary efficacy endpoints, showing significant improvement in acne vulgaris compared to placebo, with a favorable safety profile [4][5] Group 1 - The acceptance of the NDA is a significant milestone for Ascletis in its efforts to commercialize denifanstat (ASC40) [3] - Denifanstat (ASC40) has completed both Phase II and Phase III studies for the treatment of moderate-to-severe acne vulgaris [3][5] - The Phase III study results were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025, indicating the company's active engagement in scientific discourse [5] Group 2 - The Phase III study reported that all treatment-emergent adverse events (TEAEs) related to denifanstat (ASC40) were mild or moderate, with no severe adverse events observed [4] - Ascletis has licensed denifanstat (ASC40) from Sagimet Biosciences Inc. for exclusive rights in Greater China, highlighting strategic partnerships in drug development [5] - Ascletis Pharma Inc. is focused on developing and commercializing innovative therapeutics for metabolic diseases, utilizing advanced technologies in drug discovery [6]

Core Insights - Ascletis Pharma Inc. announced positive topline results from its 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist for obesity treatment, showing statistically significant weight loss compared to placebo [3][4][12] - ASC30 demonstrated a dose-dependent mean body weight reduction of 5.4%, 7.0%, and 7.7% for doses of 20 mg, 40 mg, and 60 mg respectively, with no observed plateau in weight loss [4][5] - The study included 125 participants with obesity or overweight and at least one weight-related comorbidity, achieving a placebo-adjusted mean weight loss of 7.7% at the highest dose [3][4] Efficacy and Safety - 80% of participants taking 60 mg of ASC30 lost at least 5% of their body weight, compared to 4.2% in the placebo group, and 45% lost 7% of their body weight [5] - ASC30 also met secondary endpoints, showing reductions in cardiovascular risk markers such as total cholesterol, LDL-C, triglycerides, and blood pressure across all doses [6] - No significant gastrointestinal adverse events were reported, with a total treatment discontinuation rate due to adverse events at 4.8% [7][8] Tolerability - The vomiting rate for ASC30 was approximately half that of orforglipron, indicating better gastrointestinal tolerability [7][10] - All gastrointestinal adverse events were mild to moderate, with no severe events reported [8][9] - The company anticipates further improvement in gastrointestinal tolerability in Phase III studies when titration is adjusted to every four weeks [9][10] Future Plans - Ascletis plans to submit the Phase II study data to the U.S. FDA and request an End-of-Phase II meeting in Q1 2026 [10] - The company is focused on developing ASC30 as a potential best-in-class treatment for chronic weight management, with ongoing research and development efforts [14]

Core Insights - Ascletis Pharma Inc. is focused on developing innovative treatments for metabolic diseases, with a significant breakthrough in selecting ASC37 for clinical development targeting obesity treatment [1][4] Development and Technology - ASC37 utilizes Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT), achieving an average absolute oral bioavailability of 4.2%, which is significantly higher than competitors like semaglutide, tirzepatide, and retatrutide by 9-, 30-, and 60-fold respectively [3][5] - The drug's exposure level is approximately 57 times that of retatrutide, with a half-life of about 56 hours, indicating potential for less frequent dosing, a feature preferred by patients [3][5] Regulatory and Strategic Plans - Ascletis plans to submit an Investigational New Drug Application (IND) to the U.S. FDA for ASC37 in the second quarter of 2026, demonstrating the company's commitment to addressing unmet needs in obesity treatment [4][5] - The company will host a conference call in Mandarin on December 1, 2025, to discuss ASC37's development and strategic direction in the obesity treatment landscape [4]

Core Viewpoint - Ascletis Pharma Inc. has selected ASC37 oral tablets as a clinical development candidate for obesity treatment, leveraging its proprietary Peptide Oral Transport ENhancement Technology (POTENT) to achieve significantly higher oral bioavailability compared to existing treatments [4][5][6]. Group 1: Product Development - ASC37 oral tablets achieved an average absolute oral bioavailability of 4.2%, which is approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide, respectively, in head-to-head non-human primate (NHP) studies [6]. - The drug exposure of ASC37, measured by the area under the curve (AUC), was approximately 57-fold greater than that of retatrutide in NHP studies [2][6]. - The average observed half-life of ASC37 oral tablets was approximately 56 hours, supporting once daily and less frequent oral dosing [2][7]. Group 2: Clinical Development Timeline - The company plans to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 oral tablets in the second quarter of 2026 [3][4]. - A conference call will be hosted by the company in Mandarin on December 1, 2025, to discuss further developments [3][9]. Group 3: Technological Innovation - ASC37 is developed using Ascletis' Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and is a GLP-1R, GIPR, and GCGR triple peptide agonist, demonstrating in vitro activity that is approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR, and GCGR, respectively [5][8]. - The selection of ASC37 for clinical development highlights the company's strong R&D capabilities and commitment to addressing unmet needs in obesity treatment [8]. Group 4: Company Overview - Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing and commercializing therapeutics for metabolic diseases, utilizing proprietary technologies including AISBDD and POTENT [10]. - The company has developed multiple drug candidates, including ASC30, ASC36, ASC35, and ASC37, targeting chronic weight management [10].

Core Insights - Sagimet Biosciences is advancing its clinical trials for denifanstat and TVB-3567, targeting metabolic dysfunction and acne treatment, respectively [1][2][5] Clinical Development - A Phase 1 pharmacokinetic trial for the combination of denifanstat and resmetirom is ongoing, with data readout expected in the first half of 2026 [1][11] - The trial aims to evaluate the safety, tolerability, and potential drug-drug interactions of the combination in approximately 40 healthy adult participants [5] - Sagimet has initiated a Phase 1 trial for TVB-3567, another FASN inhibitor, aimed at treating acne [2][5] Corporate Updates - Ascletis Pharma has completed its pre-New Drug Application consultation with China's NMPA for denifanstat, planning to submit an NDA for moderate-to-severe acne vulgaris treatment [1][5] - Recent promotions within the company include Marie O'Farrell as Chief Scientific Officer and Liz Rozek as Chief Legal & Administrative Officer [5] Financial Performance - As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities totaling $125.5 million [11] - Research and development expenses for the third quarter of 2025 were $9.7 million, a decrease from $12.7 million in the same period of 2024 [11] - The net loss for the third quarter of 2025 was $12.9 million, compared to a net loss of $14.6 million in the third quarter of 2024 [11][17] Market Context - MASH (metabolic dysfunction associated steatohepatitis) affects over 265 million people globally, with limited approved treatments for non-cirrhotic stages [9] - The U.S. acne market includes over 50 million individuals, with a significant need for effective chronic management options [10]

Core Insights - Ascletis Pharma Inc. has announced the co-formulation of ASC36, a once-monthly amylin receptor agonist, and ASC35, a once-monthly GLP-1R/GIPR dual agonist, for clinical development targeting obesity [5][6] Pharmacokinetics and Efficacy - The co-formulation of ASC36 and ASC35 demonstrated a comparable pharmacokinetic profile to the individual dosing of ASC36 and ASC35 in non-human primate studies, supporting once-monthly subcutaneous administration [7] - ASC36 monotherapy showed approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in diet-induced obese (DIO) rat studies, while ASC35 monotherapy exhibited approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in DIO mouse studies [2][8] - The co-formulation of ASC36 and ASC35 resulted in approximately 51% greater relative body weight reduction compared to the co-formulation of eloralintide and tirzepatide in DIO rat studies [3][9] Stability and Formulation - The co-formulation of ASC36 and ASC35 exhibited excellent chemical and physical stability, with no aggregation or precipitation at neutral pH, which is crucial for maintaining potency and reducing immunogenicity risks [6][3] Regulatory and Future Plans - The company plans to submit an Investigational New Drug Application (IND) to the U.S. FDA for the co-formulation of ASC36 and ASC35 in the second quarter of 2026 [4][5] - A conference call is scheduled for November 13, 2025, to discuss further developments [12] Technological Advancements - Ascletis utilized its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies to develop ASC36 and ASC35, enabling the design of multiple once-monthly subcutaneous ultra-long-acting peptides [6][11]

Core Insights - Ascletis Pharma Inc. presented promising data from Phase Ib studies of its obesity treatment candidates, ASC30 and the combination of ASC31 and ASC47, at ObesityWeek 2025, highlighting their efficacy and safety profiles [4][15]. Group 1: ASC30 Oral Tablet - The Phase Ib study of ASC30 oral tablet demonstrated a placebo-adjusted mean body weight reduction of up to 6.5% after 28 days of treatment, with the highest dose (60 mg) showing a maximum reduction of 9.3% [1][8]. - The study reported mild-to-moderate gastrointestinal adverse events (AEs), with no serious adverse events (SAEs) observed across all cohorts [7][8]. - The safety profile of ASC30 was consistent with or better than that of the GLP-1R agonist class, indicating it is safe and well tolerated [8]. Group 2: ASC30 Subcutaneous Injection - The Phase Ib study of ASC30 subcutaneous injection revealed an observed half-life of 46 days for the treatment formulation and 75 days for the maintenance formulation, supporting once-monthly and once-quarterly dosing [2][10]. - Similar to the oral tablet, the subcutaneous formulations were well tolerated, with only mild-to-moderate treatment-emergent adverse events reported [11][9]. - No serious adverse events or significant safety signals were detected, reinforcing the safety of ASC30 formulations [9][10]. Group 3: Combination of ASC31 and ASC47 - The combination of ASC31 and ASC47 significantly outperformed both tirzepatide and ASC31 monotherapy in weight loss, achieving a 44.8% reduction in weight compared to 19.1% for ASC31 alone, representing a 134% greater reduction [12][13]. - The combination also demonstrated superior results in body fat loss and muscle preservation, restoring the body composition of obese mice to that of healthy non-obese mice [13]. - ASC31 is a dual GLP-1R and GIPR peptide agonist, while ASC47 is designed for targeted delivery to adipose tissue, showcasing Ascletis' innovative approach in obesity treatment [12][13].

Core Insights - Ascletis Pharma Inc. has selected ASC36 as a clinical development candidate for obesity treatment, with an Investigational New Drug Application (IND) submission expected in Q2 2026 [3][4][7] Group 1: Drug Development and Efficacy - ASC36 is a once-monthly, subcutaneously administered amylin receptor agonist, demonstrating a half-life of approximately 15 days in non-human primate studies, which is three times longer than petrelintide [1][4] - In a diet-induced obese rat study, ASC36 achieved a body weight reduction of 10.01%, compared to 5.25% for petrelintide, indicating a 91% greater relative efficacy [5][6] - The drug's formulation allows for co-formulation with other peptides, such as ASC35, enhancing its therapeutic potential [2][7] Group 2: Technological Advancements - ASC36 was developed using Ascletis' Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, which facilitate the design of ultra-long-acting peptides [4][9] - The engineered properties of ASC36 support scalability advantages in manufacturing, contributing to its potential as a best-in-class treatment for obesity [5][7] Group 3: Company Strategy and Future Plans - Ascletis aims to develop ASC36 as a cornerstone therapy for cardio-metabolic diseases, with plans for combination therapies involving ASC35 [8] - A conference call is scheduled for October 30, 2025, to discuss further developments [10]

Core Insights - Ascletis Pharma Inc. is presenting multiple posters on its obesity treatment programs, including ASC30, at ObesityWeek 2025 in Atlanta, Georgia, highlighting advancements in its obesity portfolio [1][2]. Group 1: Product Details - ASC30 is an investigational GLP-1 receptor biased small molecule agonist, designed for both oral and subcutaneous administration, with patent protection until 2044 [3]. - ASC31 is a novel peptide agonist targeting GLP-1R and GIPR, showing favorable pharmacokinetics and efficacy in diet-induced obese mice [4]. - ASC47 is a once-monthly subcutaneous injected small molecule agonist targeting thyroid hormone receptor beta, designed for adipose tissue targeting [5]. Group 2: Event Information - ObesityWeek 2025 will take place from November 4 to 7, 2025, featuring the latest developments in obesity research and treatment [7]. - Presentations at the event include a full analysis of a 28-day study of ASC30 and comparisons of ASC31 and ASC47 against existing treatments [2]. Group 3: Company Overview - Ascletis Pharma Inc. focuses on developing best-in-class therapeutics for metabolic diseases, utilizing proprietary technologies for drug discovery [8].

Core Insights - Ascletis Pharma Inc. has completed enrollment in a U.S. Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation of the small molecule GLP-1 receptor agonist ASC30, targeting obesity treatment [3][4] - The Phase IIa study is a 12-week, randomized, double-blind, placebo-controlled trial involving 65 participants with obesity or overweight, all having at least one weight-related comorbidity [4][3] - Topline data from the study is expected in the first quarter of 2026, marking a significant milestone in the development of ASC30 [2][7] Study Details - The Phase IIa study evaluates the efficacy, safety, and tolerability of ASC30 in participants with a body mass index (BMI) of 30 kg/m or higher, or 27 kg/m but less than 30 kg/m [4] - The study consists of three cohorts with different doses, totaling 65 participants [4] - The ultra-long-acting SQ depot formulation of ASC30 demonstrated a 46-day observed half-life in a Phase Ib study, supporting its once-monthly administration [2][5] Technology and Development - ASC30 is developed using Ascletis' Ultra-Long-Acting Platform (ULAP), which allows for a longer half-life compared to traditional albumin-dependent technologies [6][7] - The proprietary formulation shows a favorable peak-to-trough ratio of approximately 1.5 to 1, indicating its potential as a once-monthly treatment option for obesity [7][6] - ASC30 is a first and only investigational small molecule GLP-1R biased agonist designed for both oral and subcutaneous administration [9][10] Company Overview - Ascletis Pharma Inc. is a biotechnology company focused on developing therapeutics for metabolic diseases, utilizing advanced technologies such as Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) [10] - The company is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [10]